Literature DB >> 33886267

Binding Mode of Human Norepinephrine Transporter Interacting with HIV-1 Tat.

Charles Adeniran1,2,3, Yaxia Yuan1,2, Sarah E Davis4, Ciai Lin4, Jiahui Xu4, Jun Zhu4, Chang-Guo Zhan1,2.   

Abstract

The increase of HIV infection in macrophages results in HIV proteins being released, like HIV Tat which impairs the function of monoamine transporters. HIV-infected patients have displayed increased synaptic levels of dopamine (DA) due to reduced binding and function of monoamine transporters such as the norepinephrine transporter (NET) and the dopamine transporter (DAT). Development of a three-dimensional model of the HIV-1 Tat-human NET (hNET) binding complex would help reveal how HIV-1 Tat causes toxicity in the neuron by affecting DA uptake. Here we use computational techniques such as molecular modeling to study microscopic properties and molecular dynamics of the HIV-1 Tat-hNET binding. These modeling techniques allow us to analyze noncovalent interactions and observe residue-residue contacts to verify a model structure. The modeling results studied here show that HIV-1 Tat-hNET binding is highly dynamic and that HIV-1 Tat preferentially binds to hNET in its outward-open state. In particular, HIV-1 Tat forms hydrogen bond interactions with side chains of hNET residues Y84, K88, and T544. The favorable hydrogen bonding interactions of HIV-1 Tat with the hNET side chain residues Y84 and T544 have been validated by our subsequently performed DA uptake activity assays and site-directed mutagenesis, suggesting that the modeled HIV-1 Tat-hNET binding mode is reasonable. These mechanistic and structural insights gained through homology models discussed in this study are expected to encourage the pursuit of pharmacological and biochemical studies on HIV-1 Tat interacting with hNET mechanisms and detailed structures.

Entities:  

Keywords:  Molecular docking; dopamine; molecular dynamics; norepinephrine transporter; protein−protein interaction; trans-activator of transcription

Mesh:

Substances:

Year:  2021        PMID: 33886267      PMCID: PMC8562539          DOI: 10.1021/acschemneuro.0c00792

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  81 in total

1.  1H-13C nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat protein.

Authors:  J M Péloponèse; C Grégoire; S Opi; D Esquieu; J Sturgis; E Lebrun; E Meurs; Y Collette; D Olive; A M Aubertin; M Witvrow; C Pannecouque; E De Clercq; C Bailly; J Lebreton; E P Loret
Journal:  C R Acad Sci III       Date:  2000-10

Review 2.  HIV-1 gp120 and drugs of abuse: interactions in the central nervous system.

Authors:  Peter S Silverstein; Ankit Shah; James Weemhoff; Santosh Kumar; D P Singh; Anil Kumar
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

3.  The Amber biomolecular simulation programs.

Authors:  David A Case; Thomas E Cheatham; Tom Darden; Holger Gohlke; Ray Luo; Kenneth M Merz; Alexey Onufriev; Carlos Simmerling; Bing Wang; Robert J Woods
Journal:  J Comput Chem       Date:  2005-12       Impact factor: 3.376

4.  Comparative Protein Structure Modeling Using MODELLER.

Authors:  Benjamin Webb; Andrej Sali
Journal:  Curr Protoc Bioinformatics       Date:  2016-06-20

5.  MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms.

Authors:  Sudhir Kumar; Glen Stecher; Michael Li; Christina Knyaz; Koichiro Tamura
Journal:  Mol Biol Evol       Date:  2018-06-01       Impact factor: 16.240

6.  Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse.

Authors:  Amanda N Carey; Elizabeth I Sypek; Harminder D Singh; Marc J Kaufman; Jay P McLaughlin
Journal:  Behav Brain Res       Date:  2011-12-20       Impact factor: 3.332

Review 7.  HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment.

Authors:  Deanna Saylor; Alex M Dickens; Ned Sacktor; Norman Haughey; Barbara Slusher; Mikhail Pletnikov; Joseph L Mankowski; Amanda Brown; David J Volsky; Justin C McArthur
Journal:  Nat Rev Neurol       Date:  2016-03-11       Impact factor: 42.937

Review 8.  Neuroimmunity and the blood-brain barrier: molecular regulation of leukocyte transmigration and viral entry into the nervous system with a focus on neuroAIDS.

Authors:  Clarisa M Buckner; Aimée J Luers; Tina M Calderon; Eliseo A Eugenin; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2006-04-13       Impact factor: 4.147

9.  Mutation of tyrosine 470 of human dopamine transporter is critical for HIV-1 Tat-induced inhibition of dopamine transport and transporter conformational transitions.

Authors:  Narasimha M Midde; Xiaoqin Huang; Adrian M Gomez; Rosemarie M Booze; Chang-Guo Zhan; Jun Zhu
Journal:  J Neuroimmune Pharmacol       Date:  2013-05-05       Impact factor: 4.147

10.  Mutational effects of human dopamine transporter at tyrosine88, lysine92, and histidine547 on basal and HIV-1 Tat-inhibited dopamine transport.

Authors:  Wei-Lun Sun; Pamela M Quizon; Yaxia Yuan; Matthew J Strauss; Richard McCain; Chang-Guo Zhan; Jun Zhu
Journal:  Sci Rep       Date:  2019-03-07       Impact factor: 4.379

View more
  1 in total

1.  Mutations of tyrosine 467 in the human norepinephrine transporter attenuate HIV-1 Tat-induced inhibition of dopamine transport while retaining physiological function.

Authors:  Matthew J Strauss; Katherine D Porter; Pamela M Quizon; Sarah E Davis; Steven Lin; Yaxia Yuan; Gustavo A Martinez-Muniz; Wei-Lun Sun; Chang-Guo Zhan; Jun Zhu
Journal:  PLoS One       Date:  2022-09-28       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.